Detecting longitudinal effects of haplotypes and smoking on hypertension using B-splines and Bayesian LASSO

BMC Proceedings

Table 1 Significant haplotypes and their effect estimates in 4 regions of the MAP4 gene on chromosome 3

	47911271- 47915368(EIEIEI*)						47964587-47985074(IEI*)			47998716-48005285(I*)			48022323-48037328(I*)
Hap	CGACG†			TGGCG			GGTCC			TTCG			ATTTG
Age	OR^‡	L^‡	U^‡	OR	L	U	OR	L	U	OR	L	U	OR	L	U
25	0.72	0.05	6.56	0.19	0.01	1.46	0.13	0.01	0.86	0.14	0.01	0.90	0.16	0.01	0.99
30	0.59	0.04	4.22	0.15	0.00	1.04	0.10	0.01	0.61	0.11	0.01	0.63	0.13	0.01	0.70
35	0.55	0.07	2.77	0.19	0.02	0.83	0.14	0.02	0.52	0.14	0.02	0.51	0.16	0.03	0.57
40	0.58	0.10	2.21	0.30	0.08	0.84	0.26	0.10	0.57	0.26	0.10	0.55	0.27	0.11	0.59
45	0.69	0.14	2.35	0.54	0.23	1.17	0.51	0.28	0.89	0.50	0.28	0.87	0.49	0.27	0.88
50	0.92	0.23	2.96	0.96	0.48	1.90	0.93	0.55	1.55	0.94	0.56	1.56	0.89	0.53	1.50
55	1.31	0.39	4.66	1.59	0.85	3.05	1.53	0.94	2.55	1.62	1.01	2.67	1.50	0.91	2.49
60	1.97	0.63	7.91	2.29	1.19	4.49	2.15	1.26	3.79	2.38	1.41	4.16	2.17	1.27	3.81
65	2.99	0.92	13.3	2.69	1.39	5.36	2.52	1.42	4.55	2.85	1.64	5.10	2.59	1.48	4.68
70	4.40	1.13	25.4	2.67	1.42	5.19	2.52	1.43	4.55	2.84	1.65	5.02	2.63	1.52	4.68
75	5.98	1.23	53.8	2.32	1.25	4.49	2.26	1.26	4.11	2.50	1.44	4.47	2.35	1.36	4.20
80	7.14	1.23	98.7	1.87	0.98	3.68	1.88	1.01	3.55	2.04	1.11	3.81	1.95	1.09	3.69
85	7.15	1.09	120	1.46	0.70	3.02	1.53	0.76	3.12	1.69	0.80	3.32	1.57	0.80	3.27
90	5.71	0.77	103	1.15	0.45	2.88	1.27	0.54	3.08	1.30	0.55	3.17	1.28	0.54	3.23
95	3.47	0.31	82.1	0.96	0.23	3.69	1.12	0.31	4.38	1.12	0.32	4.28	1.11	0.31	4.29

*In each of the 5-SNP-haplotype regions in the MAP4 gene, the exons (E) and introns (I) covered by the region are indicated. For example, the region from 47911271 to 47915368 covers 3 exons and 3 introns starting with an exon, indicating that the first SNP is in an exon and the last SNP is in an intron.
†This is a rare haplotype as the estimated frequency is less than 0.05.
^‡OR (odds ratio), L (lower bound of 95% credible interval [CI]), and U (upper bound of 95% CI) are presented for ages from 25 to 95 years, in an increment of 5.

ISSN: 1753-6561